Pdt Partners, LLC Cytom X Therapeutics, Inc. Transaction History

Pdt Partners, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.53 - $2.89 $211,328 - $399,175	-138,123 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$2.67 - $4.68 $8,010 - $14,040	3,000 Added 2.22%	138,123 $369,000
Q4 2021 Feb 14, 2022	BUY	$3.87 - $7.39 $113,449 - $216,637	29,315 Added 27.71%	135,123 $585,000
Q3 2021 Nov 15, 2021	BUY	$4.32 - $6.43 $129,876 - $193,311	30,064 Added 39.69%	105,808 $539,000
Q2 2021 Aug 16, 2021	BUY	$6.33 - $9.91 $197,065 - $308,518	31,132 Added 69.78%	75,744 $479,000
Q1 2021 May 17, 2021	SELL	$6.6 - $9.0 $262,825 - $358,398	-39,822 Reduced 47.16%	44,612 $345,000
Q4 2020 Feb 16, 2021	SELL	$6.47 - $7.9 $153,106 - $186,945	-23,664 Reduced 21.89%	84,434 $553,000
Q3 2020 Nov 16, 2020	SELL	$6.55 - $8.83 $28,957 - $39,037	-4,421 Reduced 3.93%	108,098 $719,000
Q2 2020 Aug 14, 2020	BUY	$7.4 - $14.64 $250,260 - $495,110	33,819 Added 42.97%	112,519 $937,000
Q1 2020 May 15, 2020	SELL	$3.61 - $8.6 $70,239 - $167,330	-19,457 Reduced 19.82%	78,700 $604,000
Q4 2019 Feb 14, 2020	BUY	$5.17 - $8.91 $41,980 - $72,349	8,120 Added 9.02%	98,157 $816,000
Q3 2019 Nov 14, 2019	BUY	$7.38 - $12.25 $664,473 - $1.1 Million	90,037 New	90,037 $664,000

50.2M

22.3K

22.9K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $79.1M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.